Dhaval Patel, MD
Cardiovascular Disease · Marietta, GANPI 1831151174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,750 of the $67,343 with a category attached, or 66.5%. Amarin Pharma, Inc. accounts for 77.9% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $48,069 and has fallen 94.4% since, to $2,695 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 504 payments — averaging $133.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$52K
- Actelion Pharmaceuticals US, Inc.$4K
- United Therapeutics Corporation$3K
- Novartis$1K
- Merck$1K
- Pfizer$992
- plus $5K from 34 others
Across 4 payments — averaging $1394.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$6K
What the payments were for
- Consulting fees$2,3003%
- Speaking & faculty fees$44,75066%
- Travel & lodging$5,4198%
- Food & beverage$14,85122%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 96 | $52,458 |
| Actelion Pharmaceuticals US, Inc. | 37 | $3,535 |
| United Therapeutics Corporation | 44 | $2,853 |
| Novartis | 50 | $1,115 |
| Merck | 43 | $1,035 |
| Pfizer | 41 | $992 |
| Amgen | 24 | $774 |
| Bayer | 27 | $730 |
| Johnson & Johnson | 29 | $647 |
| Boehringer Ingelheim | 28 | $522 |
| E.r. Squibb & Sons, L.L.C. | 18 | $350 |
| Boston Scientific | 8 | $336 |
| Medtronic(2 entities) | 2 | $198 |
| AstraZeneca | 10 | $187 |
| ZOLL Respicardia, Inc. | 1 | $158 |
| Penumbra, Inc. | 1 | $149 |
| Esperion Therapeutics, Inc. | 7 | $129 |
| Novo Nordisk | 6 | $123 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $118 |
| Asahi Intecc USA, Inc. | 1 | $112 |
| Agepha Pharma FZ LLC | 1 | $100 |
| Dentsply Sirona Inc | 1 | $100 |
| Abbott | 1 | $92 |
| Edwards Lifesciences | 2 | $57 |
| Sanofi-aventis U.S. LLC | 2 | $53 |
| Cvrx, Inc. | 2 | $50 |
| Lundbeck LLC | 2 | $45 |
| Abiomed | 1 | $33 |
| Gilead | 2 | $33 |
| Recor Medical Inc | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| GSK | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Sandoz | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$50,905
- OPSUMIT$2,761
- UPTRAVI$2,651
- ORENITRAM$457
- Adempas$200
- SYMPLICITY G3$163
- remede System$158
- Indigo System$149
- Repatha$132
- VYNDAQEL$125
- TYVASO$113
- REMODULIN$113
- ASAHI PTCA Guide Wire$112
- EVENITY$110
- LODOCO$100
- Primescan Connect$100
How this compares
$67,343 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 561 | $640,769 |
| AdempasRiociguat | 11 | $144,469 |
| EntrestoSacubitril/Valsartan | 62 | $80,961 |
| Ambrisentan | 22 | $46,856 |
| XareltoRivaroxaban | 36 | $46,095 |
| JardianceEmpagliflozin | 40 | $45,986 |
| Repatha SureclickEvolocumab | 43 | $33,465 |
| VascepaIcosapent Ethyl | 37 | $23,411 |
| FarxigaDapagliflozin Propanediol | 14 | $16,809 |
| Rosuvastatin Calcium | 513 | $6,335 |
| Ezetimibe | 273 | $6,016 |
| Metoprolol Succinate | 348 | $4,064 |
| Carvedilol | 382 | $3,296 |
| Sildenafil Citrate | 13 | $2,992 |
| Losartan Potassium | 298 | $2,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $992 | $640,769561 claims |
| BayerAdempas | $730 | $144,46911 claims |
| NovartisEntresto | $1,115 | $80,96162 claims |
| Johnson & JohnsonXarelto | $647 | $46,09536 claims |
| Boehringer IngelheimJardiance | $522 | $45,98640 claims |
| AstraZenecaFarxiga | $187 | $16,80914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Marietta
- George KramerMarietta$55K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.